Who are Sham to ranibizumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aflibercept Intravitreous Injection, Intravitreal Aflibercept Injection, Lucentis (ranibizumab), intravitreal ranibizumab injections, Syfovre™, Rescue Intravitreal Aflibercept Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sham-to-ranibizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sham to ranibizumab — Competitive Intelligence Brief

Sham to ranibizumab (Sham to ranibizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anti-VEGF agent. Area: Ophthalmology.

phase 3 anti-VEGF agent VEGF-A Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Sham to ranibizumab (Sham to ranibizumab) — Novartis. Ranibizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), preventing angiogenesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Sham to ranibizumab TARGET	Sham to ranibizumab	Novartis	phase 3	anti-VEGF agent	VEGF-A
Aflibercept Intravitreous Injection	Aflibercept Intravitreous Injection	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (placental growth factor)
Intravitreal Aflibercept Injection	Intravitreal Aflibercept Injection	Ophthalmic Consultants of Boston	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Lucentis (ranibizumab)	Lucentis (ranibizumab)	Samsung Bioepis Co., Ltd.	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
intravitreal ranibizumab injections	intravitreal ranibizumab injections	Hospital Regional de São José - Dr. Homero de Miranda Gomes	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Syfovre™	Syfovre™	Hoffmann-La Roche	marketed	Anti-VEGF aptamer	VEGF-A
Rescue Intravitreal Aflibercept Injection	Rescue Intravitreal Aflibercept Injection	Southeast Retina Center, Georgia	marketed	VEGF inhibitor / Recombinant fusion protein	VEGF-A, VEGF-B, PlGF (placental growth factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anti-VEGF agent class)

Hawaii Pacific Health · 1 drug in this class
Jaeb Center for Health Research · 1 drug in this class
Moorfields Eye Hospital NHS Foundation Trust · 1 drug in this class
Novartis · 1 drug in this class
ONL Therapeutics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sham to ranibizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/sham-to-ranibizumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab